May 20,2014

Microsoft and BD Launch Accelerator in Israel for Healthcare Startups

For the first time in the Israeli market, two major corporations will cooperate to help identify potential breakthrough startups. Microsoft and BD (Becton, Dickinson and Company), a leading global medical technology company, are working together to establish a unique accelerator experience for startups creating advancements for the healthcare industry. The program will be located at the Microsoft Ventures Accelerator in Israel and interested entrepreneurs and startups can apply now at http://www.microsoftventures.com/accelerators/telaviv.

View Analyst & Ambassador Comments
Go to original news
May 29,2014

BD to Present at Investor Healthcare Conferences

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the following investor healthcare conferences in June 2014: Jefferies 2014 Global Healthcare Conference June 4, 2014, at 10:30 a.m. ET, and Goldman Sachs 35(th) Annual Global Healthcare Conference, June 10, 2014 at 1:40 p.m. ET

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
May 29,2014

Insulet Corporation to Present at Upcoming Investor Conferences

The Jefferies 2014 Global Healthcare Conference taking place June 2-5, 2014 at the Grand Hyatt in New York City. Management is scheduled to present an overview of the Company on Monday, June 2, 2014 at 10:00 a.m. ET, and The William Blair 34th Annual Growth Stock Conference taking place June 10-12, 2014 at the Four Seasons Chicago. Management is scheduled to present an overview of the Company on Tuesday, June 10, 2014 at 3:30 p.m. CT (4:30 p.m. ET).

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Jun 02,2014

Glooko, Joslin to launch HypoMap, new platform for hypoglycemia

At the American Diabetes Association meeting next month, diabetes management software company Glooko and the Joslin Diabetes Center will launch HypoMap, a new patient-facing platform to help increase patients' awareness of hypoglycemic events. The platform will include an app for patients with diabetes that will prompt them, after a hypoglycemic event, to record symptoms, perceived causes, and self-treatments. The platform will track logged data over time and present dynamic reports that will be viewable by the patient's care team.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Jun 11,2014

Joslin Diabetes Center adds digital health division, partners with Dexcom

Boston-based Joslin Diabetes Center has created a new non-profit division, called Joslin Institute for Technology Translation (JITT), so that the healthcare organization can collaborate with companies currently developing tools for people with diabetes, according to a press release. The new division will work with physicians to design decision support tools for managing insulin and glucose tracking, partner with medical device and technology companies so that Joslin can push for the creation of digital health tools focused on diabetes, and develop educational programs that help healthcare professionals and patients adopt the new tools. Joslin's first partnership is with San Diego, California-based Dexcom, maker of continuous glucose monitoring systems for patients.

COLLABORATION PARTNERSHIP

#institution

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 16,2014

iPhone-based artificial pancreas promising in outpatient tests

An artificial pancreas system -- consisting of a continuous glucose monitor, and insulin pump, and an iPhone 4s -- has been shown to improve glucose regulation in a simulated outpatient setting in both adults and adolescents with Type 1 diabetes, according to a new paper in the New England Journal of Medicine. The adult patients had their glucose in an acceptable range (between 70 and 180 mg per deciliter) 79 percent of the time when using the system, compared to 58 percent during the control period. For the adolescents the change was smaller but still improved -- 76 percent versus 65 percent.

CLINICAL STUDY

#closed loop

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jun 04,2014

Insulet Announces Pricing of Convertible Senior Notes

Insulet Corporation (NASDAQ: PODD) today announced the pricing of a public offering of $175 million principal amount of convertible senior notes due 2019 (the "notes"). The notes will bear interest at an annual rate of 2.00% and will mature on June 15, 2019, unless earlier converted, purchased or redeemed. Insulet also granted the underwriter an option to purchase up to an additional $26.25 million principal amount of notes to cover over-allotments, if any.

View Analyst & Ambassador Comments
Go to original news
Jun 06,2014

Senseonics Raises $20 Million; Brings in New VP of Sales and Marketing

Senseonics, a privately held medical device company focused on the development and commercialization of the first fully implantable, long-term continuous glucose monitoring (CGM) system, announced that it has raised an additional $20 million of private equity financing. Senseonics also announced that Mirasol Panlilio, formerly of Abbott Diabetes Care and LifeScan, has joined the company as Vice President of Global Sales and Marketing.

FUNDING VENTURE ROUND
View Analyst & Ambassador Comments
Go to original news
Jun 13,2014

Dexcom's Forthcoming Mobile App Platform to Integrate Data from Insulet's OmniPod System

Insulet Corporation and Dexcom announced today their intention to enable Dexcom's mobile App platform, which is currently under development, to integrate data from Insulet's OmniPod System. This will be the first version of a mobile App that is capable of incorporating glucose and other diabetes-related data from patients' devices and displaying the integrated data via a smartphone App.

COLLABORATION PARTNERSHIP

#connected device

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jun 22,2014

Venture Leaders 2014 – A successful business program in Boston and New York City

1Drop Diagnostics CEO Luc Gervais was selected as a Venture Leader 2014. Chosen from over 100 candidates by a panel of investors and high-tech entrepreneurs, Luc travelled to Boston and New York City for an intense business development program.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES